This involvement ranges from expert advice to various international organisations involved in the area of general human and veterinary health to advising spin-out companies of the Erasmus University Medical Center Rotterdam that are endeavouring to bridge the gap between scientific discovery/knowledge and putting these to practical use in society.

For purposes of transparency and to avoid of possible conflicts of interest, prof. A.D.M.E. Osterhaus discloses all his interests in matters related, directly or indirectly, to his position as head of the Department of Virology of Erasmus MC.

Employment:

• A 80% position as Professor in Virology at the Erasmus University Medical Center Rotterdam.
• A 20% position as scientific advisor to ViroClinics B.V., Rotterdam. ViroClinics B.V. is a spin-out company of the Erasmus MC that performs (pre) clinical research services for industry.
• A 0% position as Professor of Environmental Virology at the State University, Utrecht.

Consultancy:

• Prof. A.D.M.E. Osterhaus performs no consultancies with companies on a personal title. Any consultancies he may perform, are through contracts between Erasmus MC on the one hand and any companies that desire consulting services of prof. Osterhaus on the other hand.

Shareholder ownership:

• Professor Osterhaus has share certificates in ViroClinics B.V. The majority of the shares in ViroClinics (> 75%) are owned by Erasmus MC through its Erasmus MC Holding B.V. To avoid any possible conflict of interest and to safeguard its employees against the possibility of unethical decisions, the Erasmus MC does not allow any of its employees to hold shares in person in any companies that are (partly) owned by Erasmus MC. As a result thereof, any shares provided by such companies to any Erasmus MC employees, are held by a Foundation Administration Office. The board of this foundation is appointed by Erasmus MC. The employees receive share certificates of their shares.
• Professor Osterhaus holds less than three percent of shares in IscoNova A.B. IscoNova A.B. is a Swedish company that predominantly works in the area of human respiratory vaccines.

Public Advisory Work:

• WHO, Director Collaborating Centre for Aboviruses and Haemorrhagic Fever Reference and Research.
• (Dutch) National Influenza Centre (NIC), Director.
• EC, Member of the Task Force Vaccines and Viral Diseases.
• EC, Member of the EC Scientific Steering Committee, ad hoc group on TSE/BSE.
• WHO, Member Strategic Advisory Group of Experts (SAGE).
• WHO, Member of the International Health Regulations (2005), roster of Experts.
• WHO, Member of the Sars aetiology network.
• WHO, Product development for aerosol measles vaccines.
• Jenner Institute, Member of the International Scientific Advisory Board.
• European Research Council Panel (ERC), Chair Advanced Grant Panel LS6: Immunity and Infection.
• (British) Department for Environment, Food and Rural Affairs, Member of the Scientific Advisory Council Sub Group for Epidemic Diseases.
• European Centre for Diseases Prevention and Control, roster of Scientists.
• - Dutch Food and Consumer Product Safety Authority, roster of scientists.
• - Council of Europe, European Pharmacopoeia Commission, Ad hoc working group “Quality of biologicals obtained from warm blood animals”.
• - AIDS fund, Scientific Advisory Council.
• - European Scientific Working Group on Influenza, Member.
• - European Parliament, Member Temporary Committee on Foot and Mouth Disease.